40+ years of excellence in custom synthesis and bioconjugation services.
Calculators, design tools, and educational content to support your research.
Advanced RNAi architectures, modification chemistry, targeted conjugation and large-scale manufacturing from discovery through commercial supply.
Bio-Synthesis supports advanced RNAi development programs requiring more than conventional duplex siRNA synthesis. Our platform combines advanced RNAi architectures, thousands of modification combinations, stereodefined chemistry, targeted conjugation technologies and large-scale manufacturing within a single workflow.
Capabilities include Dicer-Substrate siRNA (DsiRNA), Dual-Guide Triplex siRNA, Branched Duplex siRNA, Dual-Target Branched Duplex siRNA, Divalent siRNA (di-siRNA), GalNAc-siRNA conjugates and custom RNAi formats from discovery through 1,000 g+ manufacturing programs.
Build RNAi constructs beyond conventional duplex designs, including branched, multimeric, dual-guide and targeted architectures.
Control potency, stability, delivery and product quality through advanced chemistry, conjugation and analytical verification.
Scale advanced RNAi programs from feasibility studies through gram, 100 g class and 1,000 g+ manufacturing supply.
RNAi is a sequence-specific gene-silencing pathway. A delivered siRNA duplex is loaded into RISC, the guide strand directs target recognition, and complementary mRNA is cleaved to reduce protein expression.
siRNA reaches the cytosol through delivery or conjugation strategy.
Guide/passenger bias controls strand selection.
The guide strand remains active in Ago2/RISC.
Complementary target mRNA is recognized.
mRNA cleavage reduces protein expression.
Bio-Synthesis supports advanced siRNA formats and RNAi architectures beyond standard duplex designs, including branched, linked, multimeric, targeted and dual-guide constructs. This architecture portfolio is a core differentiator: each construct requires coordinated strand design, branching or linker chemistry, annealing strategy, purification, and architecture-specific analytical confirmation.
These are not simple sequence substitutions. They are engineered RNA assemblies that must be designed and manufactured as complete molecular systems.
Start with a conventional duplex when the objective is rapid target validation, screening, or a lower-complexity manufacturing route.
Standard guide/passenger duplex RNAi for target knockdown, screening and lead confirmation.
Extended Dicer-substrate RNAi designs for processing, potency and strand-bias exploration.
One passenger strand supporting two active guide strands for dual-guide and multi-target RNAi programs.
A doubler-linked passenger architecture that presents two copies of the same guide/passenger duplex design for valency and architecture studies.
Two different passenger/guide duplex systems connected through a brancher, enabling one construct to carry sequence-distinct RNAi units for two targets.
Two siRNA duplex units connected through a linker system for multivalent RNAi, enhanced tissue distribution and long-duration silencing research.
Target-binding aptamer architecture connected to RNAi payload for cell-selective delivery research.
Liver-directed RNAi conjugates using GalNAc placement, linker geometry and duplex stabilization.
Linked or multistrand RNAi systems designed for multi-target, avidity or delivery-enabled programs.
Bio-Synthesis can support programs that go beyond duplex RNAi, including doubler-linked, branched, multiguide, multivalent, ligand-conjugated and custom annealed RNAi systems.
Architecture selection affects strand count, annealing strategy, modification placement, purification, analytical characterization, and scale-up. The comparison below is a planning guide rather than a universal performance ranking.
Use the portfolio to identify formats worth evaluating, then confirm sequence-specific activity, delivery behavior, and manufacturability with matched experimental controls.
Screening, target validation, lead confirmation
Strand bias, potency, stability
Dicer processing and potency exploration
Length, polarity, modification placement
Two active guides in one assembled construct
Stoichiometry, guide activity, triplex integrity
Repeated or multi-target duplex presentation
Brancher geometry, annealing, structural purity
Multivalent, distribution, and durability research
Linker, duplex orientation, solubility
Ligand-directed delivery research
Ligand accessibility, spacer, conjugate purity
Bio-Synthesis supports advanced RNAi programs from early feasibility studies through commercial-scale manufacturing. The pathway is designed to maintain chemistry consistency, analytical control and supply continuity as programs advance toward larger production requirements.
Feasibility constructs, sequence panels and modification screening.
Lead selection, annealing strategy and analytical route planning.
Purified RNAi lots with expanded QC and process review.
Process refinement, documentation and release package planning.
Scale-matched purification, identity and purity confirmation.
High-volume supply planning with analytical comparability.
RNAi modification design should not begin with a catalog of monomers. It should begin with the intended biological outcome, the role of each strand, the selected architecture, and the manufacturing constraints. Use the engineering center below as a practical starting guide; final patterns require sequence- and application-specific evaluation.
Match chemistry to potency, stability, targeting, or immune compatibility
Understand function, placement, and manufacturing considerations
Compare discovery, stabilized, targeted, and advanced formats
Apply concise best practices before synthesis and scale-up
Lower architecture complexity; routine annealing and standard identity/purity workflow.
Higher reagent and purification demands; positional identity and impurity profile require attention.
Conjugation efficiency, hydrophobicity, and full-conjugate mass confirmation become critical.
Multiple strands, linkers, stoichiometry, branch integrity, purification, and annealing must be controlled together.
Application-specific chemistry choices depend on strand role, delivery strategy, stability requirements, immune compatibility, and the intended research model. The dedicated RNAi Modification Engineering Guide provides deeper guidance without duplicating the architecture and manufacturing content on this page.
Advanced RNAi programs require more than sequence synthesis. Bio-Synthesis combines architecture design, thousands of modification combinations, stereodefined chemistry, conjugation technologies, analytical characterization and scale-up manufacturing within a single development platform.
Explore available siRNA modifications, conjugates and delivery chemistries →
Do not see your chemistry listed? Bio-Synthesis supports thousands of modification combinations, custom RNAi architectures and project-specific analytical workflows. Contact our scientific team to discuss specialized requirements.
Canonical duplexes, conjugated siRNA, branched assemblies, and multivalent constructs do not require identical release strategies. Analytical planning should reflect strand identity, chemical modifications, annealing state, linker or branch integrity, and the intended development stage.
Final specifications and methods are selected according to architecture, scale, conjugation chemistry, and project requirements.
Identity, purity, concentration, and annealing confirmation are common starting requirements.
Triplex, branched, and divalent formats may require architecture-specific structural and assembly verification.
Full-conjugate identity, conversion, purity, and linker or ligand integrity should be evaluated together.
Select the issue closest to what you are observing to review likely causes, practical design responses, and recommended manufacturing or analytical checks.
Loss of activity can result from sequence selection, strand bias, excessive modification density, delivery limitations, or architecture-specific assembly issues.
Recommended verification:
Related RNAi modification, conjugation, and therapeutic oligonucleotide services.
Include architecture sketch, guide/passenger sequences, modifications, branch/linker design, conjugate, scale, purification and QC.
Advanced RNAi programs require quality systems that support controlled manufacturing, traceable documentation, analytical release testing, and confidential project handling. Bio-Synthesis integrates these elements throughout development and scale-up.
Bio-Synthesis supports advanced RNAi development through ISO-aligned quality systems, documented synthesis and purification workflows, analytical verification, and project-specific documentation for complex siRNA formats.
Selected references covering RNA interference discovery, siRNA mechanism, Dicer-substrate siRNA, GalNAc-siRNA delivery, aptamer-siRNA chimeras, and clinical translation of RNAi therapeutics. These citations are provided for scientific background and technology context rather than product-performance claims.
Note: These literature references provide scientific background and technology context for RNAi mechanism, siRNA design, delivery, modification chemistry, and therapeutic translation. Selection of an RNAi architecture should be evaluated in the context of sequence design, strand bias, chemical modifications, conjugation strategy, analytical requirements, target tissue, and intended research or development workflow.
Bio-Synthesis Scientific Note: Bio-Synthesis supports custom RNAi manufacturing across duplex siRNA, Dicer-substrate siRNA, dual-guide and branched RNAi constructs, divalent siRNA, multivalent RNAi systems, ligand-conjugated RNAi technologies, GalNAc-siRNA programs and other advanced oligonucleotide architectures from discovery through large-scale manufacturing.
Trusted by biotech leaders worldwide for over 45 years of delivering high-quality, fast, and scalable synthetic biology solutions.